Everett Harris & Co. CA Sells 503 Shares of GSK plc (NYSE:GSK)

Everett Harris & Co. CA decreased its position in shares of GSK plc (NYSE:GSK) by 4.9% in the fourth quarter, Holdings Channel reports. The fund owned 9,668 shares of the pharmaceutical company’s stock after selling 503 shares during the period. Everett Harris & Co. CA’s holdings in GSK were worth $358,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. FinTrust Capital Advisors LLC lifted its position in GSK by 6.9% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 4,346 shares of the pharmaceutical company’s stock worth $158,000 after acquiring an additional 281 shares during the last quarter. UMB Bank n.a. raised its position in shares of GSK by 4.8% during the third quarter. UMB Bank n.a. now owns 6,462 shares of the pharmaceutical company’s stock valued at $234,000 after buying an additional 297 shares during the last quarter. Fiduciary Group LLC raised its position in shares of GSK by 3.3% during the first quarter. Fiduciary Group LLC now owns 9,367 shares of the pharmaceutical company’s stock valued at $342,000 after buying an additional 300 shares during the last quarter. KCS Wealth Advisory raised its position in shares of GSK by 1.5% during the third quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company’s stock valued at $775,000 after buying an additional 314 shares during the last quarter. Finally, BSW Wealth Partners raised its position in shares of GSK by 5.2% during the first quarter. BSW Wealth Partners now owns 6,345 shares of the pharmaceutical company’s stock valued at $226,000 after buying an additional 316 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Price Performance

GSK stock traded down $0.13 during trading hours on Thursday, hitting $42.86. 1,854,652 shares of the stock were exchanged, compared to its average volume of 3,572,673. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88. The stock has a market capitalization of $88.22 billion, a P/E ratio of 14.27, a P/E/G ratio of 1.94 and a beta of 0.64. GSK plc has a 12 month low of $33.33 and a 12 month high of $43.84. The business’s 50-day moving average is $41.62 and its two-hundred day moving average is $38.35.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.04). The firm had revenue of $10 billion for the quarter, compared to the consensus estimate of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. Equities research analysts expect that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd will be paid a dividend of $0.3564 per share. This is a boost from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a dividend yield of 3.33%. The ex-dividend date is Thursday, February 22nd. GSK’s dividend payout ratio is 52.82%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Morgan Stanley started coverage on shares of GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy”.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.